证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－053 华润双鹤药业股份有限公司 关于全资子公司双鹤药业(海南)有限责任公司 注射用兰索拉唑通过仿制药质量和疗效一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司全资子公司双鹤药业(海南)有 限责任公司(以下简称"海南双鹤")收到了国家药品监督管理局(以下 简称"国家药监局")颁发的注射用兰索拉唑(以下简称"该药品")《药 品补充申请批准通知书》(通知书编号：2023B02191)，该药品通过仿 制药质量和疗效一致性评价(以下简称"一致性评价")。现将相关情 况公告如下： | 药品名称 | 药品通用名称：注射用兰索拉唑 | | --- | --- | | | 英文名/拉丁名：Lansoprazole for Injection | | 剂型 | 注射剂 | | 注册分类 | 化学药品 | | 规格 | 30mg | | 药品注册标准编号 | YBH07052023 | | 申请内容 | 申请进行仿制药质量和疗效一 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,738,700,207.28, representing an increase of 8.76% compared to the same period last year [6] - The net profit attributable to shareholders of the listed company was CNY 372,438,512.01, reflecting a growth of 12.19% year-on-year [6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 359,857,834.38, up by 13.26% from the previous year [6] - Basic earnings per share were CNY 0.3648, an increase of 14.63% compared to the same period last year [6] - Net profit for Q1 2023 was CNY 380,611,022.70, representing a 10.19% increase from CNY 345,356,206.23 in Q1 2022 [19] - The company reported a total profit of CNY 459,686,494.62 for Q1 2023, up from CNY 419,487,247.31 in Q1 2022, an increase of 9.99% [19] Cash Flow - The net cash flow from operating activities decreased by 35.13%, amounting to CNY 116,522,893.59 [6] - The decrease in net cash flow from operating activities was primarily due to increased tax payments and year-end bonuses paid to employees [8] - In Q1 2023, the cash inflow from operating activities was approximately CNY 2.42 billion, an increase of 7.7% compared to CNY 2.25 billion in Q1 2022 [20] - The net cash outflow from operating activities was CNY 116.52 million, down 35.1% from CNY 179.64 million in the same period last year [20] - Cash inflow from investment activities totaled CNY 202.59 million, a decrease of 69.1% from CNY 656.37 million in Q1 2022 [21] - The net cash outflow from investment activities was CNY 439.09 million, worsening from a net outflow of CNY 143.02 million in the previous year [21] - The cash outflow from financing activities was CNY 9.96 million, significantly reduced from CNY 287.51 million in Q1 2022 [21] - The net increase in cash and cash equivalents was a decrease of CNY 333.82 million, compared to a decrease of CNY 118.01 million in the same quarter last year [21] - The ending balance of cash and cash equivalents was CNY 2.28 billion, up from CNY 1.77 billion at the end of Q1 2022 [21] - The company received CNY 2.39 billion in cash from sales and services, an increase from CNY 2.19 billion in the previous year [20] - The total cash outflow for operating activities was CNY 2.30 billion, compared to CNY 2.07 billion in Q1 2022, reflecting a 11.5% increase [20] - The cash received from tax refunds was CNY 17.38 million, down from CNY 22.17 million in Q1 2022 [20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 14,754,931,255.58, which is a 1.88% increase from the end of the previous year [6] - The total assets amounted to CNY 14,754,931,255.58, compared to CNY 14,482,536,656.83 at the end of 2022 [15] - Current assets totaled CNY 7,442,019,261.79, an increase from CNY 7,164,960,901.69 at the end of 2022 [14] - Current liabilities decreased to CNY 2,883,877,993.54 from CNY 3,011,827,593.76 [15] - The total liabilities decreased to CNY 3,636,940,831.93 as of March 31, 2023, from CNY 3,752,890,948.05 at the end of 2022, a reduction of 3.09% [16] - Total equity increased to CNY 11,117,990,423.65 as of March 31, 2023, compared to CNY 10,729,645,708.78 at the end of 2022, reflecting a growth of 3.62% [16] - The equity attributable to shareholders of the listed company was CNY 10,408,710,264.30, reflecting a growth of 3.85% year-on-year [6] Investment and Financial Management - The total amount of entrusted financial management reached CNY 600 million, with an actual return of CNY 1,658,520.55 [12] - The company plans to continue its entrusted financial management strategy, indicating future financial activities [12] - The annualized return rates for entrusted financial products ranged from 1.3% to 3.3% [12] - The company’s investment income for Q1 2023 was CNY 3,896,620.38, significantly higher than CNY 87,593.21 in Q1 2022, indicating a substantial increase [17] Research and Development - Research and development expenses increased to CNY 109,634,519.50 in Q1 2023, up from CNY 83,532,252.23 in Q1 2022, marking a rise of 31.23% [17]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－025 华润双鹤药业股份有限公司 关于召开 2023 年一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 9 日(星期二)下午 15:00—16:30 会议召开地点：北京市朝阳区望京利泽东二路 1 号公司会议室 会议召开方式：现场方式 投资者可于 5 月 8 日(星期一)16:00 时前通过公司邮箱 mss@dcpc.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 华润双鹤药业股份有限公司(以下简称"公司")拟于 2023 年 4 月 28 日发布公司 2023 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2023 年一季度经营成果、财务状况，公司计划于 2023 年 5 月 9 日(星期二)下午 15:00—16:30 时举行 2023 年一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以现场方式召开，公司将针对 20 ...

Financial Performance - The total revenue for 2022 was CNY 9,446,925,267.13, representing a 3.68% increase compared to 2021[19]. - The net profit attributable to shareholders for 2022 was CNY 1,163,649,615.44, which is a 24.36% increase from the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 1,088,710,800.45, reflecting a 25.09% increase year-on-year[19]. - The basic earnings per share for 2022 was CNY 1.1235, up 25.26% from CNY 0.8969 in 2021[20]. - The weighted average return on equity increased to 11.71% in 2022, up by 1.93 percentage points from 2021[20]. - The total assets at the end of 2022 were CNY 14,482,536,656.83, a 5.90% increase compared to the end of 2021[19]. - The net cash flow from operating activities for 2022 was CNY 1,341,669,648.48, showing a slight increase of 0.06% from the previous year[19]. - The total net assets attributable to shareholders at the end of 2022 were CNY 10,022,611,149.67, a 1.18% increase from the end of 2021[19]. - The company achieved a total operating revenue of RMB 9,446,925,267.13, representing a year-on-year increase of 3.68%[34]. - The operating cost for the period was RMB 4,231,814,948.90, which increased by 5.01% compared to the previous year[34]. Dividend Distribution - The company plans to distribute a cash dividend of 2.89 CNY per 10 shares to all shareholders, resulting in an estimated total cash dividend of approximately 300.49 million CNY based on the current total share count[6]. - The total cash dividend for 2022, including the semi-annual dividend, is expected to be around 891.74 million CNY, representing a cash dividend payout ratio of approximately 76.63%[6]. - The total cash dividend for the year 2022 amounted to RMB 891,739,671.02, accounting for 76.63% of the net profit attributable to ordinary shareholders in the consolidated financial statements[129]. - The cash dividend per 10 shares for the year 2022 is proposed to be RMB 2.89 (including tax), with an estimated total cash dividend of RMB 300,492,807.79 based on the share count as of December 31, 2022[129]. Corporate Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy[5]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has established a clear and independent business operation, with no overlap in major product structures with the controlling shareholder[94]. - The company has continuously improved its internal control and compliance management system, ensuring effective operation and risk assessment[94]. - The company has established an independent financial department with a standardized accounting system, ensuring no interference from the controlling shareholder[94]. - The company has held five shareholder meetings in 2022, addressing key issues such as amendments to the articles of association and the approval of the 2021 restricted stock incentive plan[96]. Research and Development - The company launched 17 generic drugs and 6 active pharmaceutical ingredients in 2022, enhancing its R&D pipeline and technical innovation capabilities[25]. - The company reported a total of CNY 74,938,814.99 in non-recurring gains for 2022, compared to CNY 65,350,822.26 in 2021[22]. - The company has established a technology innovation committee in 2022 to enhance its R&D capabilities and collaboration with academic institutions[64]. - The company is focusing on differentiated innovation in the innovative drug sector, supported by recent regulatory improvements aimed at accelerating drug approval processes[27]. - The company aims to enhance its innovation culture and attract high-level R&D talent to accelerate the development of innovative drugs[65]. Market Strategy - The company aims to become a world-class pharmaceutical enterprise driven by innovation, focusing on chronic disease management, specialty business, and infusion business during the "14th Five-Year Plan" period[28]. - The company is actively participating in the ongoing reforms in the pharmaceutical industry, ensuring compliance with new regulations and enhancing operational efficiency[27]. - The company is committed to providing economical, safe, and effective medications to patients, responding to the increasing clinical demand driven by an aging population and rising life expectancy[27]. - The company is exploring digital economy developments in the healthcare sector, particularly in chronic disease management, to reduce costs and enhance specialization[57]. Acquisitions and Investments - The company acquired a 50.11% stake in Shenzhou Biotechnology, enhancing its capabilities in the biopharmaceutical sector[25]. - The company increased its stake in Tiandong Pharmaceutical to 70% by purchasing 31.25% from China Resources Pharmaceutical for RMB 307,187,500[41]. - The company has engaged Ernst & Young Hua Ming as its auditor for the 2022 fiscal year, with an audit fee of 2.22 million yuan[166]. - The company has completed the industrial and commercial change registration for the acquisition of Tiandong Pharmaceutical[171]. Environmental Responsibility - The company has established an environmental protection mechanism and complies with relevant regulations without any need for rectification[139]. - The company has reported no instances of exceeding emission standards for major pollutants during the reporting period[141]. - The company has implemented carbon reduction measures, including the use of photovoltaic power generation and energy-saving equipment, resulting in zero reduction in carbon dioxide equivalent emissions for the reporting period[151]. - The company has initiated a new round of environmental protection and carbon reduction projects, demonstrating a commitment to sustainable development and low-carbon transformation[153]. Employee and Executive Management - The total pre-tax compensation for executives in the reporting period amounted to 1,688.90 million yuan[99]. - The company has a total of 5,764 production staff, 2,919 sales staff, and 2,043 technical staff among its employees[121]. - The company has established a market-oriented compensation system that links employee performance to company performance[122]. - The company has implemented a performance-oriented evaluation and incentive mechanism for senior management, linking their compensation to the completion of annual operational goals[134]. Risks and Challenges - The company faces market competition risks in chronic disease medication and basic infusion fields, with plans to enhance product portfolio and expand into oncology and orthopedics to improve competitive advantage[91]. - There is a risk of product price declines due to normalized centralized procurement, which may affect the company's profitability; the company plans to adjust product structure and enhance quality through innovation[91]. - Rising production factor costs, including raw materials and labor, pose a risk; the company aims to implement lean production and improve efficiency to mitigate these costs[91]. - New drug development is a complex and costly process with inherent risks; the company is focusing on project management and enhancing R&D efficiency as part of its "14th Five-Year Plan" strategy[91].

证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－014 华润双鹤药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 会议召开时间：2023 年 4 月 4 日(星期二)下午 15:00-16:30 会议召开地点： 会议召开方式：现场、视频结合网络互动 投资者可于 2023 年 3 月 28 日(星期二)至 4 月 3 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 mss@dcpc.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 华润双鹤药业股份有限公司(以下简称"公司")于 2023 年 3 月 28 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 4 月 4 日 (星期二)下午 15:00-16:30 举行 2022 年度业绩说明会，就投资者关心 的问题进行交流。 一、说明会类型 ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 2,247,367,643.53, representing a year-on-year increase of 0.09%[6]. - The net profit attributable to shareholders for Q3 2022 was CNY 242,045,871.54, a decrease of 17.80% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 234,539,946.15, down 15.37% year-on-year[6]. - Total operating revenue for the first three quarters of 2022 reached ¥7,158,192,142.29, an increase of 4.12% compared to ¥6,875,302,884.13 in the same period of 2021[22]. - Operating profit for the first three quarters of 2022 was ¥1,240,059,119.81, up from ¥1,093,229,461.30 in 2021, reflecting a growth of 13.43%[23]. - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was ¥978,682,608.84, compared to ¥889,041,877.58 in 2021, representing an increase of 10.06%[23]. - The company reported a net profit margin of approximately 14.26% for the first three quarters of 2022, compared to 13.45% in the same period of 2021[23]. - Basic earnings per share for the first three quarters of 2022 were ¥0.9534, an increase from ¥0.8522 in 2021, representing a growth of 11.56%[24]. Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 14,629,515,359.47, reflecting a 6.97% increase from the end of the previous year[8]. - The total liabilities decreased to CNY 7,403,909,901.76 from CNY 7,522,581,989.71, showing a reduction of about 1.58%[19]. - Total liabilities as of September 30, 2022, were ¥4,110,829,278.95, compared to ¥3,199,498,957.85 at the end of 2021, marking an increase of 28.43%[21]. - Total equity as of September 30, 2022, was ¥10,518,686,080.52, slightly up from ¥10,476,551,364.99 at the end of 2021, reflecting a growth of 0.40%[21]. Cash Flow - The company reported a net cash flow from operating activities of CNY 860,480,729.27 for the year-to-date, down 8.76% year-on-year[8]. - The net cash flow from operating activities for the first three quarters of 2022 was approximately ¥860.48 million, a decrease of 8.77% compared to ¥943.10 million in the same period of 2021[26]. - The total cash outflow from operating activities was approximately ¥5.95 billion in 2022, down 3.9% from ¥6.19 billion in 2021[26]. - The net cash flow from investment activities was approximately ¥10.56 million in 2022, a significant improvement from a negative cash flow of ¥506.35 million in 2021[27]. - The cash and cash equivalents at the end of the period increased to approximately ¥2.27 billion in 2022, compared to ¥1.56 billion in 2021, marking a growth of 45.7%[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 91,872[11]. - The largest shareholder, Beijing Pharmaceutical Group Co., Ltd., held 625,795,624 shares, accounting for 59.99% of the total shares[11]. - The top shareholder, He Qianchang, holds 2,184,300 shares, while the second-largest shareholder, Li Jishan, holds 2,134,500 shares[12]. - The company has not disclosed any relationships or concerted actions among the top ten unrestricted shareholders[12]. Investments and Financial Management - The company acquired 50.11% equity in Shenzhou Biotechnology Co., Ltd. on August 19, 2022, completing the transfer registration[13]. - The company also acquired 31.25% equity in Dongying Tiandong Pharmaceutical Co., Ltd. on September 26, 2022, with the board's approval on August 2, 2022[13]. - The company has entrusted financial management with a total amount of RMB 150 million, with an annualized return rate of 1.5% to 3.3%[14]. - Another entrusted financial management of RMB 200 million has an annualized return rate of 1.6% to 3.2%, with actual returns of RMB 3,093,011.31[15]. - The company has a total of RMB 250 million in entrusted financial management with an annualized return rate of 1.6% to 3.35%[16]. - The company reported a total of CNY 1,950,000,000.00 in entrusted financial management, with actual returns of CNY 12,529,589.11[18]. - The annualized yield rates for entrusted financial management products ranged from 1.3% to 3.4%[18]. - The company has plans for future entrusted financial management, indicating ongoing investment strategies[18].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 4,910,824,498.76, representing a 6.07% increase compared to CNY 4,629,988,963.08 in the same period last year[19]. - The net profit attributable to shareholders of the listed company reached CNY 736,636,737.30, a 23.89% increase from CNY 594,597,810.60 year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 691,905,809.78, up 23.99% from CNY 558,024,102.77 in the previous year[19]. - The net cash flow from operating activities was CNY 668,019,806.97, showing a slight decrease of 0.63% compared to CNY 672,285,429.53 in the same period last year[19]. - Basic earnings per share increased by 25.60% to 0.7159 CNY compared to the same period last year[20]. - Diluted earnings per share also rose by 25.60% to 0.7159 CNY year-on-year[20]. - The weighted average return on equity improved by 1.03 percentage points to 7.26%[20]. - In the first half of 2022, the company achieved a revenue of 4.85 billion CNY, representing a year-on-year growth of 6%, and a net profit of 737 million CNY, up 24% year-on-year[27]. - The company reported a net profit of approximately CNY 571.42 million for the first half of 2022, compared to a net profit of CNY 268.88 million in the same period of 2021, indicating a significant increase[107]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.89 per 10 shares (including tax) to all shareholders, pending approval at the shareholders' meeting[6]. - The total cash dividend to be distributed is estimated to be CNY 300,345,128.79 based on the number of shares eligible for distribution as of June 30, 2022[6]. Assets and Liabilities - As of the end of the reporting period, the net assets attributable to shareholders amounted to CNY 9,892,936,202.41, a decrease of 0.13% from CNY 9,905,495,654.72 at the end of the previous year[19]. - The total assets of the company were CNY 13,926,683,716.32, reflecting a 1.83% increase from CNY 13,676,050,322.84 at the end of the previous year[19]. - The total liabilities increased to CNY 3,436,734,357.89 from CNY 3,199,498,957.85, marking a rise of about 7.41%[89]. - The company's equity attributable to shareholders decreased slightly to CNY 9,892,936,202.41 from CNY 9,905,495,654.72, a decline of approximately 0.13%[89]. Research and Development - The company is actively increasing R&D investment to enhance competitiveness in innovative drugs amid industry differentiation[23]. - Research and development expenses rose by 7.24% to approximately ¥193.49 million, up from ¥180.42 million in the previous year[30]. - The company is focusing on innovation, with projects like the Fascin protein inhibitor for cancer treatment and CX2101 for antiviral drug development underway[27]. Market and Industry Trends - The pharmaceutical industry is experiencing significant downward pressure on growth, with hospital and retail pharmacy sales showing negative growth in the first half of 2022[23]. - The normalization of volume-based procurement is expected to continue, with over 350 drug names targeted for procurement by each province[23]. - The chronic disease business remains the largest segment for the company, significantly impacted by national volume-based procurement policies, with a focus on optimizing resource allocation and digital marketing strategies[24]. Environmental and Social Responsibility - The company has initiated a three-year action plan for environmental protection and carbon reduction, collecting 47 projects aimed at energy saving and carbon reduction[63]. - The company conducted 4 rounds of public medical education activities under the "Thousand County Plan," benefiting over 20,000 doctors across more than 500 counties[64]. - The company is committed to enhancing grassroots medical capabilities and improving healthcare services in rural areas[64]. Compliance and Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees reported during the period[8]. - The company has committed to not reduce its ordinary shares during the repurchase period, which lasts for three and six months from December 27, 2021[70]. Financial Management - The company has invested CNY 150 million in a wealth management product with an expected annual return of 1.5% to 3.3%[42]. - The total amount of entrusted financial management reached CNY 1,550,000,000.00, with actual returns of CNY 12,529,589.11[44]. - The company reported a financial income of CNY 24,416,144.07 in the first half of 2022, compared to a financial expense of CNY 21,635,575.88 in the same period of 2021[95]. Shareholder Information - The total number of ordinary shareholders reached 81,283 by the end of the reporting period[80]. - Beijing Pharmaceutical Group Co., Ltd. holds 625,795,624 shares, accounting for 59.99% of the total shares[80]. - The total number of shares before the change was 1,043,237,710, which decreased to 1,025,631,410 after the issuance of restricted shares[77].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 2,518,174,975.92, representing a 4.59% increase year-over-year[6]. - Net profit attributable to shareholders was CNY 331,971,014.87, reflecting a 15.99% increase compared to the same period last year[6]. - The net profit after deducting non-recurring gains and losses was CNY 317,717,474.58, up by 19.48% year-over-year[6]. - Basic and diluted earnings per share were both CNY 0.3182, marking a 15.99% increase[6]. - Operating profit for Q1 2022 was ¥424,020,624.79, up 18.3% from ¥358,500,072.98 in Q1 2021[20]. - Net profit for Q1 2022 was ¥345,356,206.23, representing a 16.2% increase from ¥297,164,529.40 in Q1 2021[21]. - Total comprehensive income for Q1 2022 was ¥345,355,685.67, an increase from ¥297,164,492.56 in Q1 2021[21]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 44.34%, amounting to CNY 179,637,208.19, primarily due to a reduction in the balance of receivables[6][8]. - Cash flow from operating activities for Q1 2022 was ¥179,637,208.19, a decrease of 44.2% compared to ¥322,732,752.17 in Q1 2021[22]. - Cash inflow from operating activities totaled ¥2,245,590,205.14 in Q1 2022, down from ¥2,399,083,493.29 in Q1 2021[22]. - Cash outflow from operating activities was ¥2,065,952,996.95 in Q1 2022, compared to ¥2,076,350,741.12 in Q1 2021[22]. - The cash and cash equivalents decreased to CNY 2,713,587,721.04 from CNY 2,834,035,295.68, representing a decline of about 4.26%[16]. - The cash and cash equivalents at the end of Q1 2022 amounted to approximately ¥1.77 billion, slightly up from ¥1.72 billion at the end of Q1 2021[23]. - The cash and cash equivalents decreased by approximately ¥118.01 million in Q1 2022, contrasting with an increase of ¥230.81 million in Q1 2021[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,713,457,608.57, a slight increase of 0.27% from the end of the previous year[6]. - The total liabilities of the company as of March 31, 2022, were CNY 3,177,908,131.69, slightly down from CNY 3,199,498,957.85, a decrease of approximately 0.67%[18]. - The company's equity attributable to shareholders increased to CNY 9,956,373,840.47 from CNY 9,905,495,654.72, reflecting a growth of about 0.52%[18]. - Accounts receivable increased significantly to CNY 1,496,814,196.36, up from CNY 1,232,982,001.21, marking an increase of approximately 21.43%[16]. - Inventory levels decreased to CNY 1,555,242,234.23 from CNY 1,665,455,865.49, indicating a reduction of about 6.61%[16]. - The company's fixed assets decreased to CNY 2,616,211,709.99 from CNY 2,629,698,915.82, a decline of approximately 0.52%[17]. Investments and Financial Management - The total amount of entrusted financial management reached 1,450,000,000.00 CNY during the reporting period[14]. - The company reported an actual return of 4,090,890.41 CNY from its entrusted financial management activities[14]. - The annualized yield rates for various entrusted financial products ranged from 1.3% to 3.48%[13]. - The company has plans for future entrusted financial management, indicating ongoing investment strategies[14]. - The expected returns from entrusted financial management were linked to derivative market performance[13]. - The company’s financial products included structured deposits linked to financial derivatives, enhancing potential returns[14]. Shareholder Information - The top shareholder, Beijing Pharmaceutical Group Co., Ltd., holds 625,795,624 shares, accounting for 59.99% of the total shares[9]. - The company reported a total of 42,810 common shareholders at the end of the reporting period[9]. Management and Governance - The company did not apply the new accounting standards for the first time in 2022, which may impact future financial reporting[23]. - The company’s management team includes key personnel such as Feng Yi and Fan Yanxi, responsible for accounting and financial oversight[23].

Financial Performance - The total revenue for 2021 was CNY 9,111,516,930.74, representing a 7.14% increase compared to CNY 8,503,938,229.78 in 2020[16]. - The net profit attributable to shareholders of the listed company decreased by 6.91% to CNY 935,685,482.77 from CNY 1,005,161,634.08 in the previous year[16]. - The net profit after deducting non-recurring gains and losses was CNY 870,334,660.51, down 9.56% from CNY 962,334,953.03 in 2020[16]. - The cash flow from operating activities was CNY 1,340,920,963.61, a slight decrease of 1.41% compared to CNY 1,360,158,210.19 in 2020[16]. - The total assets increased by 10.14% to CNY 13,676,050,322.84 at the end of 2021, up from CNY 12,416,486,664.94 at the end of 2020[16]. - The basic earnings per share for 2021 was CNY 0.8969, down 6.91% from CNY 0.9635 in 2020[17]. - The weighted average return on equity decreased by 1.49 percentage points to 9.78% from 11.27% in the previous year[17]. - The gross profit margin for the overall business was 55.91%, a decrease of 7.67 percentage points from the previous year[34]. - The operating cost increased by 28.13% to CNY 4.03 billion from CNY 3.15 billion, leading to a decrease in overall gross margin[32]. Research and Development - The company established a three-tier R&D system and significantly increased R&D investment in 2021, resulting in notable R&D achievements[22]. - The company launched an innovation division focused on acquiring innovative drugs and technologies, successfully introducing two Class 1 innovative drugs in less than a year[22]. - Research and development expenses rose by 40.74% to CNY 409.59 million, attributed to increased investment in product layout[32]. - The company has over 120 ongoing research and development projects, focusing on generic drugs and consistency evaluation[59]. - The company established an innovation division in 2021 to enhance its research and development capabilities, focusing on high-end generics and innovative drugs[59]. - The company is committed to increasing its R&D efforts and collaborating with external research institutions to enhance its product line[53]. Market and Business Strategy - The company aims to leverage digital marketing strategies to enhance the promotion of chronic disease products, ensuring competitive advantages[27]. - The company plans to expand its specialty business through self-research, product collaboration, and acquisitions[27]. - The company is focusing on the development of biosimilars, with two new products expected to enter the market by the end of 2022[93]. - The company plans to continue expanding its business operations and has approved a proposal for daily related transactions in 2021[89]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, targeting a completion date by Q3 2022[103]. - The company aims to maintain a competitive edge by adjusting its product structure and enhancing quality through innovation in response to the challenges posed by centralized procurement policies[84]. Governance and Compliance - The company has established a governance structure that ensures clear responsibilities and effective supervision, complying with relevant laws and regulations[86]. - The company has implemented a performance-oriented evaluation and incentive mechanism, linking executive compensation to the achievement of annual operational goals[87]. - The company has developed a comprehensive internal control management system to enhance operational efficiency and risk compliance[87]. - The company has established specialized committees within the board of directors to enhance decision-making and governance[86]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[6]. - The company has ensured compliance with laws and regulations regarding related party transactions, emphasizing fairness and transparency in dealings[145]. Environmental Responsibility - The company has initiated a three-year action plan for environmental protection and carbon reduction, collecting 47 projects aimed at energy saving and carbon reduction[138]. - The company has achieved environmental management system certification for 14 out of 18 production bases by the end of the reporting period[137]. - The company is classified as a key pollutant discharge unit and is subject to environmental protection regulations[129]. - The company has monitored various emissions regularly, including nitrogen oxides and wastewater pollutants, ensuring compliance with environmental standards[135]. Shareholder Information - The total number of ordinary shareholders increased from 35,417 to 39,197 during the reporting period, representing a growth of approximately 10%[166]. - Beijing Pharmaceutical Group Co., Ltd. remains the largest shareholder, holding 625,795,624 shares, which accounts for 59.99% of the total shares[167]. - The company did not experience any changes in its share capital structure during the reporting period[166]. - The company plans to repurchase between 22.1764 million and 23.5 million shares, representing 2.13% to 2.25% of the total share capital[175]. Financial Management - The company has engaged in wealth management with a total amount of RMB 1 billion, with an outstanding balance of RMB 800 million[156]. - The company has multiple wealth management products with varying annualized returns ranging from 1.40% to 5.15%[158]. - The company plans to continue its entrusted financial management strategy, indicating a commitment to maintaining liquidity and optimizing returns[160][161]. - The actual returns from entrusted financial products amounted to approximately 6.5 million CNY across different financial institutions, with the highest return being 2.26 million CNY from China Construction Bank[160][161].